Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4,198Cash on Hand
0mo Cash Runway
Follow ARTL by emailGet an email when ARTL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ARTL, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 9, 2026 ·
Listing The SEC approved Nasdaq's new $5M minimum market value of listed securities rule on July 22, 2026, and a temporary stay was announced July 29. Nasdaq has proposed tying the rule's start to the end of the stay, with comments due October 29, 2026. Artelo is among about 180 affected companies and is monitoring the rule. Form 8-K · SEC filing
Aug 27, 2026 ·
Shareholder vote Artelo Biosciences will effect a 1-for-9 reverse stock split, effective 5:00 p.m. ET on August 28, 2026, with shares trading split-adjusted from August 31, 2026. Outstanding shares fall from 4,929,966 to about 547,774. Form 8-K · SEC filing · Press release
Aug 20, 2026 ·
Amended quarterly report for the period ended Jun 30, 2026 Form 10-Q/A · SEC filing
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
ARTL holds $4,198 in cash and short-term investments (as of Sep 30, 2026) and burns about $3.8M/quarter from operations,
an estimated runway of 0 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway not available
ATM program on file since May 2026 +15
Shelf registration (S-3, May 2026) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ARTL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.